Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and HoldThe Motley Fool • 02/26/24
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock UpZacks Investment Research • 02/22/24
CRISPR Therapeutics AG (CRSP) Presents at Citi 2024 Virtual Oncology Leadership Summit Conference (Transcript)Seeking Alpha • 02/21/24
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/21/24
CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?Zacks Investment Research • 02/16/24
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership SummitGlobeNewsWire • 02/15/24
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/13/24
European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)GlobeNewsWire • 02/13/24
CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should KnowZacks Investment Research • 02/03/24